Recent studies have demonstrated that tumor-derived Th17 cells produce low levels of TGF-β and IL-10 after stimulation with anti-CD3 in vitro and express CTLA4, FoxP3, and CD25 as Treg cell markers, while they do not suppress tumor progression. This evidence concerns the gene TGFB1 and neoplasm.